← All trials
NCT04838301
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Jan 31, 2024
- Completion date
- Jun 30, 2024
- First posted
- Apr 9, 2021
- Last posted
- Sep 28, 2021
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ArizonaLead sponsor
- University of ArizonaReponsible party - principal investigator
- National Institute on Aging (NIA)Collaborator
- University of Southern CaliforniaCollaborator
- Syneos HealthCollaborator
- ADM Diagnostics, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.